VitriVax Raises 87 Million Dollars for Lyme Vaccine and Formulation

Company VitriVax Event Type Series C financing ($87 million; previously missed 18 Nov event) Modality Thermostable vaccine formulation (ALTA atomic layering) Asset Lyme disease vaccine candidate Target Borrelia (antigen undisclosed) Disease Area Lyme disease Summary VitriVax announced an $87 million Series C on November 18…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *